We are committed to leveraging our intellectual property and the product development expertise of our highly experienced management team to enable vascular targeted therapy to realize its true potential and to bring much needed new therapies for orphan oncology indications to cancer patients worldwide. We have a portfolio of preclinical and clinical stage candidates focused on areas of significant unmet need that we believe can bring significant value to our shareholders.
Our common stock is traded on the OTCQB Market under the symbol “MATN”.
POSITIVE EARLY RESULTS FOR ARTIVEDATM IN TREATING COVID-19. Download this Report (PDF 480 KB)
Click HERE for Stonegate analyst report.
Click HERE for Zacks SCR analyst report.
Click HERE for Zacks SCR upgrade analyst report - 12/16/2020.
Click HERE for Litchfield Hills Research analyst report.
Click HERE for Litchfield Hills Research analyst report updated - 1/6/2021.
Click HERE for Litchfield Hills Research analyst report upgrade price target to $4 from $3 - 3/3/2021.
We are headquartered in Agoura Hills, California.